Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Journal Volume
28
Journal Issue
6
Pages
1117
Date Issued
2022-03-15
Author(s)
Le, Xiuning
Sakai, Hiroshi
Felip, Enriqueta
Veillon, Remi
Garassino, Marina Chiara
Raskin, Jo
Cortot, Alexis B
Viteri, Santiago
Mazieres, Julien
Smit, Egbert F
Thomas, Michael
Iams, Wade T
Cho, Byoung Chul
Kim, Hye Ryun
Chen, Yuh-Min
Patel, Jyoti D
Bestvina, Christine M
Park, Keunchil
Griesinger, Frank
Johnson, Melissa
Gottfried, Maya
Britschgi, Christian
Heymach, John
Sikoglu, Elif
Berghoff, Karin
Schumacher, Karl-Maria
Bruns, Rolf
Otto, Gordon
Paik, Paul K
Abstract
Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups.
Subjects
CELL LUNG-CANCER; CAPMATINIB; MUTATIONS; AMPLIFICATION; INHIBITORS; DIAGNOSIS; SURVIVAL; IMPACT
Publisher
AMER ASSOC CANCER RESEARCH
Type
journal article